Compare HUMA & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUMA | SAR |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | 184 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.6M | 361.6M |
| IPO Year | N/A | N/A |
| Metric | HUMA | SAR |
|---|---|---|
| Price | $1.35 | $22.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $6.19 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 7.8M | 87.5K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $444.16 | N/A |
| Revenue Next Year | $248.39 | $0.39 |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $20.78 |
| 52 Week High | $2.84 | $25.64 |
| Indicator | HUMA | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 47.77 |
| Support Level | $0.89 | $21.58 |
| Resistance Level | $1.72 | $22.82 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 75.52 | 50.91 |
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.